Infosys-Cognizant trade-secrets battle nears end as Dallas court passes order
The court has asked the two IT services companies to get on a conference call with it to settle parts of their dispute. The legal tussle began when Cognizant accused Infosys of stealing trade secrets pertaining to its healthcare software last August.
A 10-month legal battle between two of the world’s largest information technology (IT) services companies may be drawing to a close, with a Dallas court asking Cognizant and Infosys to join a conference call with it to settle parts of their dispute.
In a 23 May order, the court welcomed both parties to discuss matters pertaining to the case over a call with the court.
Also read: Acquisitions power Cognizant's performance over peers, but concerns linger
“This is not an invitation to engage in ex parte communications or obtain advisory rulings from the court," judge David L. Horan clarified. “Rather, the parties are required to attempt to resolve by agreement any disputes on non-dispositive pretrial discovery matters by meaningfully conferring before seeking the court’s involvement."
The order essentially directs Cognizant and Infosys to discuss and settle any disagreements about what information they'll share before trial.
“But, if that fails to resolve the dispute, the parties are encouraged, where appropriate, to seek an informal telephone conference with the court to attempt to resolve simple and straightforward disputes in an efficient and cost-effective manner."
No need to specify trade secrets, court says
In a separate order on the same day, the court asked Cognizant to provide by 13 June details of people with knowledge of Infosys’s healthcare software product and the names of individuals it believes stole its proprietary software. It also directed the IT services company to identify all measures it has taken to protect the confidentiality of the information it considers to be trade secrets by the same day.
Still, the court ruled that Cognizant was not expected to further specify the trade secrets it alleged were misappropriated beyond what it had already stated, dismissing Infosys’s motion to compel Cognizant to clearly identify the allegedly stolen trade secrets, which the court termed ‘interrogatory no. 1.’
“The court denies Infosys’s motion to compel Cognizant to serve a supplemental answer to Interrogatory No. 1 at this time," read the order.
Cognizant said in response to Mint's queries on Tuesday, “The court made clear that Infosys cannot shield itself behind a self-imposed protective order to avoid disclosing information it is contractually and legally obligated to provide. We have been surprised by Infosys’s refusal to produce this information—particularly given our clear entitlement to it under the parties’ agreement and through standard discovery rules. The only reasonable explanation for Infosys’s continued concealment is that the withheld documents will reveal the true scope and impact of Infosys’ misconduct."
A query emailed to an Infosys spokesperson remained unanswered.
How the tussle began
The legal battle began when Cognizant accused Infosys of stealing trade secrets pertaining to its healthcare software last August. Infosys denied the allegations and responded with its own counterclaims, suggesting Cognizant had not properly identified the trade secrets it alleged were stolen.
Infosys upped the ante after it publicly named Cognizant chief executive S Ravi Kumar in a court filing, accusing Cognizant of hiring him to slow down the development and rollout of a competing software. Kumar, an Infosys veteran, left the company in October 2022 and joined Cognizant as CEO in January 2023.
Also read: Accenture and Infosys have beaten TCS. What is N. Chandrasekaran planning?
In a 10 March filing, Cognizant called Infosys’s claims ‘preposterous’ and ‘absurd’, adding that Kumar and two other people named by Infosys were hired on the basis of their skills.
Cognizant, which follows a January-December financial calendar, ended 2025 with $19.74 billion in revenue, while Infosys, which follows an April-March financial calendar, ended FY25 with $19.28 billion in revenue.
Heathcare sector matters more to Cognizant
However, Cognizant has a bigger share of the healthcare sector. The Nasdaq-listed company gets almost a third of its revenue, about $5.9 billion, from clients in the health sciences sector, while Infosys gets 7.3% of its revenue, about $1.4 billion, from clients in this space.
Cognizant acquired healthcare software QNXT and Facets in 2014 by taking over TriZetto, which provides administrative solutions in healthcare. Health insurance companies in the US use these products to process claims.
Infosys built its own healthcare product, Helix, in 2022, as an alternative to QNXT and Facets. The two companies have since been servicing clients in the healthcare sector using their software products.
Also read | Mint Primer: What the US-China trade deal means for IT services companies
The legal tussle comes amid a slowdown in India's $283 billion IT services industry, and both companies have been grappling with their own set of issues. Cognizant has struggled to post growth after discounting its recent acquisitions, which make up almost half of its full-year revenue growth of 8.2% in constant currency terms. Kumar, 53, has been tasked with turning the company around. Infosys, on the other hand, has been finding it hard to bag large deals. The company missed its guidance and forecast its slowest growth in over a decade for FY26 amid economic uncertainties.
topics
